In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

First data of a nurse-outpatient secondary prevention program

Session Poster Session III - Saturday 08:30 - 12:30

Speaker Elio Venturini

Congress : EuroPrevent 2017

  • Topic : preventive cardiology
  • Sub-topic : Risk Factors and Prevention
  • Session type : Poster Session
  • FP Number : 765

Authors : E Venturini (Cecina (LI),IT), M Siragusa (Cecina (LI),IT), N Bosio (Cecina (LI),IT), L Mesisca (Cecina (LI),IT), R Testa (Cecina (LI),IT)

E Venturini1 , M Siragusa1 , N Bosio1 , L Mesisca1 , R Testa1 , 1Department of Cardiology - Civic Hospital - Cecina (LI) - Italy ,

European Journal of Preventive Cardiology ( April 2017 ) 24 ( Supplement 1 ), 169

Purpose: the prevalence of low adherence (A) in coronary artery disease (CAD) can be up to 43%; is associated with poor control of coronary risk factors, but also facilitates the recurrence of the disease. We evaluated the effects of an outpatient education program,made exclusively by nurses, after an acute coronary syndrome (ACS)
Methods: 82 P (64.6% men and 35.4% women, mean age 68.3 ± 12.7), after an ACS, at 15 days, 3 months and 6 months were subjected to a comprehensive nursing education sessions supervised by cardiologists. The topics of discussions were: information on coronary risk factors and healthy lifestyles; targets, frequency,doses, side effects of drugs and its chemical and trade name; filling of a diary to record the dose and when taking the drug; simplification of the treatment regimen; involvement of caregivers particularly in the case of cognitive impairment. The questionnaire Morisky Medication Adherence Scale 8-item (MMAS) was the tool to calculate the level of A. The level of LDL-cholesterol (LDL-C) was used as an indirect assessment of the A to statins treatment. A recent historical control group of 50 P usual care was used for comparison.
Results: at sixth month on the basis of the results MMAS, 9 (11%) of P had low, 22 (26.8%) average, and 51 (62.2%) high AT. In the control group, the results were, respectively, 10 (20%), 22 (44%) and 18 P (36%). Thus, 37.8% of P were non-adherent compared with 64% of the usual care group. Also the number of P that reached the LDL-C target (<70mg/dl) was higher than in the control group (67, 81.7% vs. 19, 38%, p <.01).
Conclusions: despite the benefits of secondary prevention, the medium term mortality and morbidity after ACS is still too high. Low A and medical inertia can adversely affect the P outcomes. An education coronary program, managed entirely by nurses, but under the supervision of a cardiologist can improve the level of A to the prescribed therapy. This implies a better LDL-C control, a major coronary risk factor whose positive impact on the prognosis of coronary patients is well known.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are